Clinical and Mutation Analysis of Patients with Best Vitelliform Macular Dystrophy or Autosomal Recessive Bestrophinopathy in Chinese Population

Table 2

Clinical data of patients with BVMD.

Patient Number	Gender	Age (years)	Phenotype	Stages		Therapies	VA (first visit)		VA (after therapies)
				OD	OS		OD	OS	OD	OS
1	Male	30	BVMD	vitelliform	vitelliform	-	0.8	0.12	-	-
2	Female	34	BVMD	vitelliform	vitelliruptive	-	defect	defect	-	-
3	Male	8	BVMD with OS CNV	vitelliruptive	atrophic/cicatricial	OS IVB1	0.6	0.07	0.6	0.1
4	Male	20	BVMD	vitelliruptive	pseudohypopyon	-	defect	defect	-	-
6	Male	25	BVMD with OD CNV	atrophic/cicatricial	vitelliruptive	OD; IVB3/IVC; 1/IVR1; OS IVC1	0.25	0.8	1.0	1.0
8	Female	49	BVMD	vitelliruptive	vitelliruptive	OU PDT1	0.5	0.5	0.4	0.4
9	Female	30	BVMD	vitelliruptive	vitelliruptive	-	1.0	1.2	-	-
10	Male	38	BVMD	pseudohypopyon	vitelliruptive	-	0.25	0.25	-	-
12	Male	4	BVMD with OD fundus hemorrhage	atrophic/; cicatricial	vitelliform	-	0.075	0.4	-	-

BVMD: best vitelliform macular dystrophy. VA: visual acuity. OD: oculus dexter, right eye. OS: oculus sinister, left eye. OU: oculus uterque, binoculus. CNV: choroidal neovascularization. IVB: intravitreal injection of bevacizumab. IVC: intravitreal injection of conbercept. IVR: intravitreal injection of ranibizumab. PDT: photodynamic therapy. Asterisks mean times of therapy. Blank sections mean no data available.